Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| RMTI | ROCKWELL MEDICAL, INC. | 2025-10-16 18:58:19 | 1.2 | 0.01 | 0.84 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RMTI | 0001041024 | ROCKWELL MEDICAL, INC. | US7743743004 | 529900Y6YUB5X93MMD77 | 383317208 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 30142 WIXOM ROAD | WIXOM | MI | 48393 | UNITED STATES | US | 8004493353 | 30142 WIXOM ROAD, WIXOM, MI, 48393 | 30142 WIXOM ROAD, WIXOM, MI, 48393 | ROCKWELL MEDICAL TECHNOLOGIES INC | Pharmaceutical industry | 1996 | Stuart Paul | 269 | http://rockwellmed.com/ | 53,981,386 | 34,430,352 | 34,430,352 | Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD). | 2025-10-10 23:25:04 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 53,981,386 | -37,067,428 | -40.7116 | 34,056,920 | 4,722,303 | 16.0981 |
| 2023 | 91,048,814 | 79,952,152 | 720.5063 | 29,334,617 | 16,781,944 | 133.6922 |
| 2022 | 11,096,662 | -17,910,614 | -61.7452 | 12,552,673 | -81,433,797 | -86.6442 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Megan Timmins | Chief Legal Officer, Secretary | 2024 | 412,000 | 0 | 69,500 | 185,400 | 13,800 | 749,889 |
| Jesse Neri | Chief Financial Officer | 2024 | 300,000 | 0 | 46,329 | 135,000 | 12,000 | 539,458 |
| Mark Strobeck | Chief Executive Officer | 2024 | 566,500 | 0 | 139,000 | 453,200 | 13,800 | 1,310,878 |
| Marc Hoffman | Chief Medical Officer | 2023 | 260,226 | 0 | 35,161 | 0 | 159,940 | 486,782 |
| Megan Timmins | Chief Legal Officer, Secretary | 2023 | 412,000 | 0 | 39,065 | 164,800 | 8,944 | 660,288 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 244 |
| 2023 | 237 |
| 2022 | 253 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 101,489,000 | 83,612,000 | 72,810,000 |
| Cost Of Revenue | 84,005,000 | 74,908,000 | 68,733,000 |
| Gross Profit | 17,484,000 | 8,704,000 | 4,077,000 |
| Research And Development Expenses | 19,000 | 1,107,000 | 3,119,000 |
| General And Administrative Expenses | 14,108,000 | 12,142,000 | 15,644,000 |
| Operating Expenses | — | — | — |
| Operating Income | 608,000 | -6,670,000 | -16,780,000 |
| Net Income | -480,000 | -8,439,000 | -18,679,000 |
| Earnings Per Share Basic | -0.03 | -0.37 | -1.89 |
| Earnings Per Share Diluted | -0.03 | -0.37 | -1.89 |
| Weighted Average Shares Outstanding Basic | 31,058,539 | 23,322,915 | 9,866,844 |
| Weighted Average Shares Outstanding Diluted | 31,058,539 | 23,322,915 | 9,866,844 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 15,662,000 | 8,983,000 | 10,102,000 |
| Marketable Securities Current | 5,940,000 | 1,952,000 | 11,390,000 |
| Accounts Receivable | 8,291,000 | 10,901,000 | 6,259,000 |
| Inventories | 5,778,000 | 5,871,000 | 5,814,000 |
| Non Trade Receivables | — | — | 6,259,000 |
| Other Assets Current | — | — | — |
| Total Assets Current | 37,030,000 | 28,770,000 | 35,310,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 5,785,000 | 6,402,000 | 2,194,000 |
| Other Assets Non Current | 528,000 | 527,000 | 523,000 |
| Total Assets Non Current | 22,178,000 | 23,403,000 | 11,325,000 |
| Total Assets | 59,208,000 | 52,173,000 | 46,635,000 |
| Accounts Payable | 2,869,000 | 4,516,000 | 4,053,000 |
| Deferred Revenue | 46,000 | 46,000 | 1,731,000 |
| Short Term Debt | 0 | 0 | 1,631,000 |
| Other Liabilities Current | 6,275,000 | 7,149,000 | 7,702,000 |
| Total Liabilities Current | 14,091,000 | 16,637,000 | 17,691,000 |
| Long Term Debt | 8,472,000 | 8,293,000 | 7,555,000 |
| Other Liabilities Non Current | 0 | 14,000 | 14,000 |
| Total Liabilities Non Current | 12,531,000 | 14,245,000 | 14,838,000 |
| Total Liabilities | 26,622,000 | 30,882,000 | 32,529,000 |
| Common Stock | 3,000 | 3,000 | 1,000 |
| Retained Earnings | -397,678,000 | -397,198,000 | -388,759,000 |
| Accumulated Other Comprehensive Income | 54,000 | -1,000 | 163,000 |
| Total Shareholders Equity | 32,586,000 | 21,291,000 | 14,106,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 2,180,000 | 1,444,000 | 576,000 |
| Share Based Compensation Expense | 1,292,000 | 932,000 | 315,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | -2,610,000 | 4,642,000 | 346,000 |
| Change In Inventories | 332,000 | -1,176,000 | 2,101,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | -1,410,000 | -2,720,000 |
| Change In Accounts Payable | -1,647,000 | 463,000 | 314,000 |
| Change In Other Liabilities | -1,034,000 | -376,000 | 2,534,000 |
| Cash From Operating Activities | 4,202,000 | -9,412,000 | -17,414,000 |
| Purchases Of Marketable Securities | 5,858,000 | 5,701,000 | 21,297,000 |
| Sales Of Marketable Securities | 2,003,000 | 15,301,000 | 19,182,000 |
| Acquisition Of Property Plant And Equipment | 1,011,000 | — | — |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -4,866,000 | -3,045,000 | -2,396,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 10,181,000 | 14,861,000 | 15,016,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | 0 |
| Cash From Financing Activities | 7,348,000 | 11,342,000 | 16,632,000 |
| Change In Cash | 6,679,000 | -1,119,000 | -3,178,000 |
| Cash At End Of Period | 15,662,000 | 8,983,000 | 10,102,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | 847,000 | 1,209,000 | 1,470,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -0.03 | -0.37 | -1.89 |
| Price To Earnings Ratio | -68 | -5.1081 | -0.537 |
| Earnings Growth Rate | -91.8919 | -80.4233 | 440 |
| Price Earnings To Growth Ratio | 0.74 | 0.0635 | -0.0012 |
| Book Value Per Share | 1.0492 | 0.9129 | 1.4296 |
| Price To Book Ratio | 1.9444 | 2.0704 | 0.71 |
| Ebitda | 2,954,000 | -4,694,000 | -16,167,000 |
| Enterprise Value | 56,169,419.56 | 43,390,309.35 | 9,098,846.66 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 0.26 | 0.3895 | 0.6512 |
| Capital Expenditures | 1,563,000 | 5,652,000 | 284,000 |
| Free Cash Flow | 2,639,000 | -15,064,000 | -17,698,000 |
| Return On Equity | -0.0147 | -0.3964 | -1.3242 |
| One Year Beta | 1.4879 | 2.5654 | 1.0065 |
| Three Year Beta | 1.3949 | 1.3723 | 1.1277 |
| Five Year Beta | 1.267 | 1.2449 | 1.0604 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Strobeck Mark | Director, President and CEO | 2025-10-01 | 6,926 | D | 330,826 |
| Neri Jesse | SVP and CFO | 2025-10-01 | 886 | D | 125,728 |
| Chole Timothy | SVP and CCO | 2025-10-01 | 2,868 | D | 125,299 |
| Hunter Heather | SVP, Chief Operating Officer | 2025-10-01 | 2,868 | D | 135,391 |
| Strobeck Mark | Director, President and CEO | 2025-07-01 | 6,926 | D | 337,752 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Rise Advisors, LLC | 2025-09-30 | 258 | 215 | 1.2 |
| OSAIC HOLDINGS, INC. | 2025-06-30 | 390 | 465 | 0.8387 |
| Squarepoint Ops LLC | 2025-06-30 | 45,091 | 53,173 | 0.848 |
| MORGAN STANLEY | 2025-06-30 | 11,020 | 12,995 | 0.848 |
| Tower Research Capital LLC (TRC) | 2025-06-30 | 5,655 | 6,669 | 0.848 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| iSHARES TRUST | 2025-06-30 | iShares Micro-Cap ETF | IWC | 70,805 | 60,042.64 | 0.0073 |
| VANGUARD INDEX FUNDS | 2025-06-30 | Institutional Select Shares | VSEMX | 355,638 | 301,581.02 | 0.0003 |
| VANGUARD INDEX FUNDS | 2025-06-30 | Institutional Plus Shares | VEMPX | 355,638 | 301,581.02 | 0.0003 |
| VANGUARD INDEX FUNDS | 2025-06-30 | ETF Shares | VXF | 355,638 | 301,581.02 | 0.0003 |
| VANGUARD INDEX FUNDS | 2025-06-30 | Institutional Shares | VIEIX | 355,638 | 301,581.02 | 0.0003 |